Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer | MicrobiomeTrials← Back to trialsNCT06128252
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2024-09-01Est. Completion: 2027-06-30
Enrollment target: 96 participants Locations- Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
- Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
- The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
- Xi-jing Hospital, Xi'an, Shaanxi, China
- Tang-Du Hospital, Xi'an, Shaanxi, China
- Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
- Xi 'an International Medical Center Hospital, Xi'an, Shaanxi, China
- The Second Affilated Hospital Of Xi'an Jiaotong University (Xibei Hospital), Xi'an, Shaanxi, China
- Xi'an NO.3 hospital, Xi'an, Shaanxi, China
- The Third People's Hospital of Chengdu, Chengdu, Sichuan, China
- Cancer Hospital Affiliated to Xinjiang Medical University, Ürümqi, Xinjiang Uygur Autonomous Region, China
- The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing, China
- The First Affiliated Hospital of Army Medical University (Southwest Hospital), Chongqing, China
- Army Specialty Medical Center of PLA (Daping Hospital), Chongqing, China
Other microbiome trials you might be interested in
Advanced CancerPancreatic Cancer
This is a prospective, single-arm, pilot feasibility clinical trial designed to evaluate the feasibility and safety of a…
Toronto, CanadaEst. completion Jun 1, 2027
Chemotherapy Effect
This study focuses on patients with H. pylori-positive resectable locally advanced adenocarcinoma of the gastric and oes…
Guangzhou, ChinaEst. completion Dec 28, 2026
Fudan University Shanghai Cancer Center (FUSCC), Shanghai, ChinaPhase 3
Completed
Gastro-Oesophageal Cancer
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current sta…
Scottsdale, United StatesCompleted Jan 14, 2025